anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous studies suggest that there are brain anatomical and functional in patients with anxiety disorder and obsessive-compulsive disorder (OCD). However, it remains unclear whether these abnormalities can be used for the diagnosis of anxiety disorder、OCD and prediction of treatment effects. It is also unclear whether there are shared imaging biomarkers between different subtypes of anxiety disorder and OCD.And it still lacks reliable neuroimaging biomarkers in anxiety disorder and OCD. Based on the previous studies, this study aims to examine the whole-brain anatomical and functional abnormalities in 30 general anxiety disorder (GAD),30 panic disorder(PD),30 social anxiety disorder,30 obsessive-compulsive disorder patients and 30 healthy controls by using a combination of cross-section and longitudinal study designs, including a longitudinal study in patients with anxiety disorder and OCD with 4 weeks of selective serotonin reuptake inhibitor (SSRI) paroxetine treatment.First, neuroimaging biomarkers are definitively selected in subjects at different subtypes of anxiety disorder and OCD population for the purpose of diagnosis by using a cross-section design. After that, a longitudinal study is conducted in patients with anxiety disorder and OCD with 4 weeks of paroxetine treatment to validate that the selected neuroimaging biomarkers can be used to predict treatment response of medication. The definitively selected neuroimaging biomarkers are expected to be useful for the diagnosis of anxiety disorder and OCD, and prediction of treatment effects; and finally be helpful for understanding the pathophysiology of anxiety disorder and OCD.
Cardiovascular magnetic resonance imaging (CMR) was performed on day 5 and day 90 after PCI to evaluate myocardial infarction size, microvascular obstruction area, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). Physical examination, blood routine examination, and coagulation function examination were performed before the first dose, on the 7th, 30th, and 90th day after PCI. The examination before the first dose was conducted to accept the examination results from the current onset to the first dose.Electrocardiogram (ECG) was performed before the first dose, day 2, day 7, day 30, and day 90 after PCI, and the test results from the period after PCI to the first dose were received. Vital signs were examined before the first dose, day 1 to day 7, day 30, and day 90 after PCI, and the results of the examination from the first onset to the first dose were accepted during the examination before the first dose. Blood biochemical tests were performed before the first dose, from day 2 to day 4, day 7, day 30, and day 90 after PCI. The results of the examinations from the first onset to the first dose were accepted during the examination before the first dose. High-sensitivity troponin I(hs-cTnI) or troponin I(cTnI) and amino-terminal B-type natriuretic peptide precursor (NT-proBNP) or B-type natriuretic peptide (BNP) were tested before first administration and on days 2, 3, 4, and 7 after PCI. Examination results from the time after PCI to the time before initial administration; Creatine kinase isoenzyme (CK-MB) tests were performed before the first dose, 12 hours after the first dose, day 2 (if it coincided with 12 hours after the first dose, no repeat blood collection was required), day 3, and day 4. The test results from the period after PCI to the period before the first dose were accepted. Tumor markers were detected and immunogenic blood samples were collected before the first dose and on the 30th day after PCI. The tumor markers were examined before the first dose. Urine routine examination was performed before the first dose and on the 90th day after PCI. The examination before the first dose accepted the examination results from the onset of the disease to the first dose. Drug combinations, adverse events, and cardiovascular events were recorded during the trial.
A computer system generates and manages clinical studies. A first collection of clinical documents is analyzed to extract clinical study goals and corresponding clinical study design components. A second collection of documents is analyzed to extract value sets indicating a mapping between clinical concepts and data elements of clinical information. The extracted clinical study design information and value sets are stored in a hierarchical structure within a repository that relates the clinical study goals, design components, concepts, and the data elements. A new clinical study is generated for a desired clinical study goal based on pattern recognition applied to the extracted clinical study design information and value sets in the repository using the repository. Embodiments of the present invention further include a method and program product for generating and managing clinical studies in substantially the same manner described above.
A therapeutic composition 5 comprising an inner portion 7 and a biocompatible membrane fully or partially surrounding the inner portion. The biocompatible membrane comprises at least two layers: a first layer 1 of a porous, non-woven network of thermoplastic polyurethane polymer fibres formed by electrospinning and having a porosity of greater than or equal to 50%; an average pore diameter of less than 5µm; and has a thickness in the range 10 to 250µm; and a second layer 2 of a porous, non-woven network of thermoplastic polymer fibres formed by electrospinning. The mean average fibre diameter and/or the average pore diameter of the second layer is greater than that of the first layer. The inner portion preferably contains a therapeutic agent selected from therapeutic cells, a drug, a nucleic acid, a nucleotide, a protein, a polypeptide, an antibody, a particle such as a lipid nanoparticle, an extracellular vesicle or exosome. The nucleic acid may comprise DNA, RNA, RNAi, SaRNA or SiRNA. The inner portion may comprise pancreatic beta cells, islet cells, with or without carrier material, hepatocytes, erythrocytes or leukocytes such as CAR-T cells. The composition can be used in the treatment of diabetes.
Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac sodium, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
Novel taxoidx of genenl fonnuli (I), the preparation thereof and pharmaceutical corapotitioni containing tame, ire disclosed. In genera] formula (I). Z is a hydrogen atom or a radical of genenl formula (H), wherein RI i* an optionally subctitmed benroyl radical or a radical R2-O-CO-, where Rj if an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl. bicycloalkyl, option-ally nibatituted phenyl or heterocyclyl radical; Rj is an alkyl. alkenyl, alkynyl. cycloaDcyl. phenyl. naphtrryl or aromatic hcte-rocyclic radical; IU a a bydroxy radical or an aftoxy. alkeny-loxy. optionally tubtdtuted alkynyioxy, alkanoyloxy, alkenoy-loxy. alkynytoxy, alkoxyacetyl or alkyloxycarbonyioxy radical, or a cyctoalkyloxy. cycloalkenyloxy. arylcarbonyloxy or hete-Tocyclylcarbonyloxy radical; and Rj is an optionally lubttituted alkoxy radical or a cycloalkyloxy or cycloalxeayloxy radical The novel compounds of general formula (I), wherein Z i* a radical of general formula (II), have remarkable antitumoral and antinec-plattic properties.
The present invention relates to an application of Brazil hematoxylin in the preparation of an inhibitor of an anti-apoptotic protein Mcl-1. Specifically disclosed is use of Brazil hematoxylin as an inhibitor or a competitive binding agent of the protein Mcl-1. Further provided is an application of Brazil hematoxylin as a drug for potential treatment of Parkinson's disease. It is discovered in the present invention for the first time that Brazil hematoxylin can act on the anti-apoptotic protein Mcl-1, and promote the separation of a pro-apoptotic protein bonded to the anti-apoptotic protein Mcl-1 by means of competitive binding of Mcl-1, thereby achieving the effect of inhibiting the anti-apoptotic protein. At the same time, the released pro-apoptotic protein can play a role in promoting apoptosis. IC50 of Brazil hematoxylin for Mcl-1 is 3.47 μM.
Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
Civilian PTSD is a widespread psychiatric condition and is commonly underestimated in terms of prevalence and morbidity, at least in the United States and probably world-wide. The magnitude of the public health impact of PTSD is highlighted by recent epidemiologic findings. Kessler, et al, estimated a 7.8% lifetime prevalence for PTSD in a representative national sample of 5877 persons aged 15-54. In part, this high prevalence is due to the high occurrence of trauma exposure over a lifetime. Common types of Civilian PTSD include serious physical attack or assault, rape, sexual assault, transportation accidents, exposure to death/homicide or serious injury, life-threatening accidents, threats of injury with fire, floods, weapons, natural disasters and civilian exposure to military attacks. Persons with PTSD are usually unaware that they have this disorder and because treatment professionals have been inadequately sensitized to high prevalence of this condition, the condition is markedly undiagnosed and thereby undertreated. The risk of PTSD is not restricted to the psychiatric population. In general, persons with PTSD seek help in general medical and not mental health settings. Individuals with PTSD are at increased risk of co-morbid psychiatric disorders including depression, alcohol and drug abuse, panic disorder, agoraphobia and personality disorders. It is associated with a substantially higher suicide risk, hospitalization rates, and increased utilization rates of non-psychiatric medical services as well as mental health services.
The present invention relates to a plaster for treating hyperosteogeny, which is prepared from prepared rehmannia root, tortoise beetle, loranthus parasiticus, mountain sadako, wolfberry fruit, blood antler, herba speranskiae tuberculatae, vomiting nut, raw wild aconite, astragalus, black bone vine, rhododendron molle, black-tail snake, chaenomeles fruit, kansui root, licorice root, camphor, borneol, sal ammoniac, asafetida, drynaria, prepared fleece flower root, bezoar, oil, skin, etc. The present invention is characterized in that the plaster can improve the curative effect of affected parts which are applied with the plaster. Meanwhile, the present invention can avoid the side effect of the whole body medication of oral medicine. The present invention has the advantages of scientific prescripton, particular material selection and simple production method. The curative effect of the plaster of the present invention amounts for 82%, and the total effective rate amounts for 98.9% through the trial of the 353 patients. Therefore, the present invention is an ideal plaster for treating hyperosteogeny and rheumatism.
PURPOSE:To produce a liq. detergent and a dentifrice excellent in washing power and polishing power and having substantially a transparent appearance on a visual sense. CONSTITUTION:In an inorg. powder having low refractive index and the liq. detergent and the dentifrice using this powder as an abrasive material, this inorg. powder having low refractive index of <=1.40 in an aqueous medium is composed of porous particles consisting essentially of SiO2 or SiO2 and Al2O3 and having 1-50mum average grain size in which fine pores having substantially <=100nm diameter occupies 8-80vol.% of the vol. of each particle, and the fine pores are blocked off at the vicinity of the particle surface and a communication with the outside is interrupted.
Participants who are deemed ctDNA responders (reduction in ctDNA by 50% or more) on post-chemo testing will undergo active surveillance and continued serial ctDNA testing at regular intervals as defined by the study protocol. Patients will also undergo surveillance imaging as defined in the study protocol. At the time of first radiographic or ctDNA progression (to be assessed every 12 weeks in conjunction with radiographic assessment), the patient will be offered treatment with pembrolizumab.
BACKGROUND: Acute functional decline is a common reason for hospital admission for older people, often caused by an acute deterioration of an underlying chronic illness. However, occasionally a rare condition is detected.
CASE PRESENTATION: A woman in her eighties was admitted to hospital with acute functional decline. Hyponatraemia, urinary tract infection and pulmonary embolism were initially diagnosed. She developed increasing difficulties in using her legs, and assessment led to the diagnosis of varicella- zoster virus myelitis, which was treated with intravenous acyclovir. After a brief stay in the rehabilitation unit, the patient's condition acutely deteriorated, leading to readmission with neurovascular septic embolism and microvascular haemorrhage in the brain. Anticoagulation was terminated. After 52 days she was discharged to a nursing home for further rehabilitation.
INTERPRETATION: Our article presents a case of acute functional decline caused by a rare condition. Collaboration between the geriatric, neurological and infectious disease departments was needed. When treated rapidly with targeted therapy, the prognosis for myelitis is often good.
Thrombotic microangiopathy (TMA) is a rare but serious side effect of tyrosine kinase inhibitor (TKI) therapy. Previous case reports of renal TMA have usually occurred in the first few months of TKI initiation with only very few cases occurring within 2-3 years. We report a case of a patient who was referred to the Nephrology service for nephrotic syndrome and worsening renal function after 8 years of sunitinib therapy for metastatic clear cell carcinoma of the kidney. Renal biopsy showed chronic TMA without another secondary aetiology identified. With discontinuation of sunitinib and pharmacological optimisation of his hypertension, his renal function and proteinuria both significantly improved. No relapse or recurrence of disease activity was noted after a year of follow-up. This case highlights the importance of remaining vigilant for the development of renal TMA even after an extended duration of TKI therapy.
Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Stimulation will remain inactive for the 20 minutes. At the same time, they will be guided to recognize landscapes that do not refer to the recognition of laterality.
In our clinic, cesarean operation is performed with blunt and sharp dissections in the abdomen followed by transverse incision of the lower segment to the uterus. After uterotomy, the incision will be closed with single or double layer suture. The single layer suture technique will be performed with suturing by taking approximately 1 cm of tissue from the upper and lower segments where the mucosa and muscular layer are stitched together and locking them continuously at intervals of about 1 cm. On the first layer of the double layer suture technique, about 0.5 cm of tissue is taken from the upper and lower segments and the mucosa is closed by locking about 1 cm intervals. On the second layer, about 1 cm of tissue is taken from lower and upper segments of the muscle layer and both sides will be sutured with continue non-locking suture technique. The uterotomy incision will be closed with multifilament, synthetic, braided, suture that absorbable in about 60-90 days. In both groups prophylactic intramuscular 1 gr Cefazolin and 20 intravenous units of oxytocin will be administered intravenously.

Randomization will be done according to the patient's ID numbers. Patients who have a single digit of the end of ID number will be closed with continuous locking with suture, and patients who have a single digit of the end of ID number will be closed with double suture. The suture technique used and the number of additional hemostatic sutures will be obtained from the operation note. In addition, demographic characteristics of the patients, duration of operation, hemoglobin changes within 24 hours post-operatively, infant birth weight, hospitalization time, estimated blood loss during surgery will be examined in the study. The estimated blood loss will be recorded from the level of the initial aspirator bag after the surgery.

Enrolled patients will be called for control 6 months after surgery. It will be evaluated by a single obstetrician in a supine position under standard conditions, with empty bladder, with transvaginal ultrasonographic device. Measurements will be made when the endometrium, lower uterine segment and cervix are visible in the sagittal section of the uterus during transvaginal ultrasonography. Scar defect will define as a hypoechoic wedge-shaped image that causes discontinuity in the structure of the endometrium which extending downward from the anterior line to the serosa. The width and depth of the sagittal plane of the defect and the axial length of the axial plane will be measured. Ultimately, these measurements will be taken volumetrically.
The invention discloses an ovarian cyst-relieving enema and a preparation method thereof. The ovarian cyst-relieving enema comprises 10 to 15 parts of seaweed, 12 to 15 parts of kelp, 6 to 10 parts of cassia twig, 10 to 15 parts of poria cocos, 10 to 15 parts of talc, 20 to 30 parts of plantain seed, 10 to 15 parts of turtle shell, 30 to 40 parts of raw oyster shell, 5 to 8 parts of beautiful sweetgum fruit, 20 to 35 parts of red sage root, 15 to 20 parts of red peony root, 10 to 12 parts of rhizoma alismatis, 5 to 8 parts of cassia bark and 10 to 12 parts of lychee seed. The ovarian cyst-relieving enema is a pure Chinese medicine enema fixing preparation. The enteroclysis method adopting the ovarian cyst-relieving enema is a novel method of traditional Chinese medicine external treatment on ovarian cyst, and supplies a gap of research and development of an external fixing agent-form enema at home and abroad. A pharmacological experiment proves that reactive oxygen metabolic disturbance is a main pathogenesis of ovarian cyst. A toxicity experiment proves that the ovarian cyst-relieving enema is safe and has no toxic and side effect. A clinical study proves that the ovarian cyst-relieving enema has obvious and good effects and is simple, convenient and cheap.
No adequate animal reproduction studies have been conducted with fluocinolone acetonide. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Fluocinolone acetonide when administered subcutaneously at a dose of 0.13 mg/kg/day (approximately 10,000 times the daily clinical dose of RETISERT), during days 6 to 18 of pregnancy in the rabbit, induced abortion at the end of the third and at the beginning of the fourth gestational week. When administered subcutaneously to rats and rabbits during gestation at a maternal toxic dose of 50 mcg/kg/day (approximately 4,000 times the clinical dose of RETISERT), fluocinolone acetonide caused abortions and malformations in a few surviving fetuses.

There are no adequate and well-controlled studies in pregnant women. RETISERT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Laser lithotripsy mechanisms can cause the chemical decomposition of stone components and the emergence of different end products. However, the potentially toxic end products formed during thulium fiber laser (TFL) lithotripsy of cystine stones have not been sufficiently investigated. The aim of our in vitro study is to analyze the chemical content of the gas products formed during the fragmentation of cystine stone with TFL. Human renal calculi consisting of 100% pure cystine, calcium oxalate monohydrate, or uric acid were fragmented separately with TFL in experimental setups and observed for gas release. After the lithotripsy, only the cystine stones showed gas formation. Gas chromatography-mass spectrometry was used to analyze the gas qualitatively, and scanning electron microscopy with energy-dispersive X-ray spectroscopy (SEM-EDX) and X-ray diffraction was used to examine the dried cystine stone fragments. Fragmentation of the cystine stones released free cystine, sulfur, hydrogen sulfide, and carbon disulfide gas. The SEM-EDX and X-ray diffraction analyses revealed that the free cystine in the dried fragments contained 43.1% oxygen, 28.7% sulfur, 16.1% nitrogen, and 12.1% carbon atoms according to atomic weight. The detection of potentially toxic gases after lithotripsy of cystine stones with TFL indicates a risk of in vivo production. Awareness needs to be increased among healthcare professionals to prevent potential inhalation and systemic toxicity for patients and operating room personnel during TFL lithotripsy of cystine stones.
Background: Following its introduction in 2018, the Single-Port (SP) robotic platform has been increasingly utilized for various approaches of robotic radical prostatectomy (RARP). Despite the demonstrable benefits in enhancing postoperative outcomes, there has been limited evidence on its perioperative morbidity, especially when compared to the gold-standard multiport (MP). This study sought to compare the perioperative morbidity between SP and MP-RARP. Methods: A retrospective review was performed on 911 patients who underwent RARP between January 2015 and May 2023. At our institution, SP-RARP has been performed since October 2018 with Extraperitoneal and Transvesical (TV) techniques. To reduce the risk of selection bias, only MP-RARP cases performed before October 2018 were included. Baseline clinicodemographic and perioperative parameters were collected. Perioperative complications were classified in accordance to the Clavien-Dindo system with postoperative complications and readmission reported within 90 days of surgery. Statistical analysis was performed with R Packages for Statistical Computing with descriptive statistics as presented. Results: Of the 484 SP and 322 MP-RARP cases included in our analysis, one intraoperative complication was reported, which pertained to a small enterotomy during TV SP-RARP. Postoperative complications were identified in 14.5% and 14.6% of SP and MP-RARP cases (p = 0.989), respectively. Major complication represents 4.1% of the SP and 3.4% of MP cohorts. The 90-day rates of hospital readmission following SP and MP-RARP were 5.6% and 4.9%, respectively (p = 0.717). Limitations of this study included the retrospective single surgeon, single institution nature of our series that also included the early learning curve experience associated with the novel SP platform. Conclusion: This comparative study provided evidence highlighting the low rates of perioperative complication and readmission following SP-RARP that were comparable to the Transperitoneal MP approach. The low morbidity associated with SP-RARP supports its wider application as an addition to the contemporary minimally invasive surgical armamentariums for prostate cancer.
Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.